Basic mechanisms of gabitril (tiagabine) and future potential developments

Epilepsia

Volumn 40, Issue SUPPL. 9, 1999, Pages

  Meldrum, Brian S ^a   Chapman, Astrid G ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antiepileptic; Epilepsy; GABA; Mode of action; Tiagabine

Indexed keywords

1 [2 (BENZHYDRYLIDENEAMINOOXY)ETHYL] 1,2,5,6 TETRAHYDRO 3 PYRIDINECARBOXYLIC ACID; 1 [3 (9H CARBAZOL 9 YL)PROPYL] 4 (2 METHOXYPHENYL) 4 PIPERIDINOL; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; CARRIER PROTEIN; ISOPROTEIN; NIPECOTIC ACID; NNC 05 0341; NNC 05 1965; NNC 05 1973; NNC 05 2045; TIAGABINE; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID UPTAKE; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; COMPLEX PARTIAL SEIZURE; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; GRAND MAL SEIZURE; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; NONHUMAN; PAIN; PRIORITY JOURNAL;

EID: 0032797278     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb02087.x     Document Type: Conference Paper

References (63)

1. Macdonald RL, Meldrum BS. Principles of antiepileptic drug action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:61-75.
2. B receptor pharmacology. Annu Rev Pharmacol Toxicol 1993;33:109-47.
3. B receptors uncovers similarity to metabotropic glutamate receptors. Nature 1997;386:239-46.
4. B receptors that mediate inhibition of GABA and glutamate release in human neocortex. Br J Pharmacol 1997;120:60-4.
5. Borden LA. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int 1996;29:335-56.
6. McIntire SL, Reimer RJ, Schuske K, Edwards RH, Jorgensen EM. Identification and characterization of the vesicular GABA transporter. Nature 1997;389:870-6.
7. Sagné C, El MS, Isambert MF, et al. Cloning of a functional vesicular GABA and glycine transporter by screening of genome databases. FEBS Lett 1997;417:177-83.
8. Minelli A, Brecha NC, Karschin C, DeBiasi S, Conti F. GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex. J Neurosci 1995;15: 7734-46.
9. Minelli A, DeBiasi S, Brecha NC, Zuccarello LV, Conti F. GAT-3, a high-affinity GABA plasma membrane transporter, is localized to astrocytic processes, and it is not confined to the vicinity of GABAergic synapses in the cerebral cortex. J Neurosci 1996;16: 6255-64.
10. Ribak CE, Tong WMY, Brecha NC. GABA plasma membrane transporters. GAT-1 and GAT-3, display different distributions in the rat hippocampus. J Comp Neurol 1996;367:595-606.
11. Augood SJ, Herbison AE, Emson PC. Localization of GAT-1 GABA transporter mRNA in rat striatum: cellular coexpression with GAD67 mRNA, GAD67 immunoreactivity, and parvalbumin mRNA. J Neurosci 1995;15:865-74.
12. De Biasi S, Vitellaro-Zuccarello L, Brecha NC. Immunoreactivity for the GABA transporter-1 and GABA transporter-3 is restricted to astrocytes in the rat thalamus. A light and electron-microscopic immunolocalization. Neuroscience 1998;83:815-28.
13. Itouji A, Sakai N, Tanaka C, Saito N. Neuronal and glial localization of two GABA transporters (GAT1 and GAT3) in the rat cerebellum. Brain Res Mol Brain Res 1996;37:309-16.
14. Morara S, Brecha NC, Marcotti W, Provini L, Rosina A. Neuronal and glial localization of the GABA-transporter GAT-1 in the cerebellar cortex. Neuroreport 1996;7:2993-6.
15. Honda S, Yamamoto M, Saito N. Immunocytochemical localization of three subtypes of GABA transporter in rat retina. Brain Res Mol Brain Res 1998;33:319-25.
16. Evans JE, Frostholm A, Rotter A. Embryonic and postnatal expression of four gamma-aminobutyric acid transporter mRNAs in the mouse brain and leptomeninges. J Comp Neurol 1996;376: 431-46.
17. Yan XX, Cariaga WA, Rihak CE. Immunoreactivity for GABA plasma membrane transporter, GAT-1, in the developing rat cerebral cortex: transient presence in the somata of neocortical and hippocampal neurons. Brain Res Dev Brain Res 1997;99:1-19.
18. Quick MW, Corey JL, Davidson N, Lester HA. Second messengers, trafficking-related proteins, and amino acid residues that contribute to the functional regulation of the rat brain GABA transporter GAT1. J Neurosci 1997;17:2967-79.
19. Lai CT, Tanay VAMI, Charrois GJR, Baker GB, Bateson AN. Effects of phenelzine and imipramine on the steady-state levels of mRNAs that encode glutamic acid decarboxylase (GAD67 and GAD65), the GABA transporter GAT-1 and GABA transaminase in rat cortex. Naunyn Schmiedebergs Arch Pharmacol 1998;357: 32-8.
20. 3H|tiagabine binding to sections from mice brain. Epilepsy Res 1995;21:79-88.
21. During MJ, Ryder KM, Spencer DD. Hippocampal GABA transporter function in temporal lobe epilepsy. Nature 1995;376:174-7.
22. Akbar MT, Rattray M, Williams RJ, Chong NWS, Meldrum BS. Reduction of GABA and glutamate transporter messenger RNAs in the severe-seizure Genetically Epilepsy Prone rat. Neuroscience 1998;85:1235-51.
23. Hirao T, Morimolo K, Yamamoto Y, et al. Time-dependent and regional expression of GABA transporter mRNAs following amygdala-kindled seizures in rats. Brain Res Mol Brain Res 1998; 54:49-55.
24. Williamson A, Telfeian AE, Spencer DD. Prolonged GABA responses in dentate granule cells in slices isolated from patients with temporal lobe sclerosis. J Neurophysiol 1995;74:378-87.
25. Horton RW, Collins JF, Anlezark GM, Meldrum BS. Convulsant and anticonvulsant actions in DBA/2 mice of compounds blocking the reuptake of GABA. Eur J Pharmacol 1979;59:75-83.
26. Meldrum BS, Pedley T, Horton R, Anlezark G, Franks A. Epileptogenic and anticonvulsant effects of GABA agonists and GABA uptake inhibitors. Brain Res Bull 1980;5:685-90.
27. Frey HH, Popp C, Löscher W. Influence of inhibitors of the high affinity GABA uptake on seizure thresholds in mice. Neuropharmacology 1979;18:581-90.
28. Ali FE, Bondinelli WE, Danbridge PA, et al. Orally active and potent inhibitors of gamma aminobutyric acid uptake. J Med Chem 1985;28:653-60.
29. Andersen KE, Braestrup C, Gronwald FC, et al. The synthesis of novel GABA uptake inhibitors. I. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate. J Med Chem 1993;36:1716-25.
30. Andersen KE, Begtrup M, Chorghade MS, et al. The synthesis of novel GABA uptake inhibitors. Part 2. Synthesis of 5-hydroxytiagabine, a human metabolite of the GABA reuptake inhibitor tiagabine. Tetrahedron 1994;50:8699-710.
31. Yunger LM, Fowler PJ, Zarevics P, Settler PE. Novel inhibitors of gamma-aminobutyric acid (GABA) uptake; anticonvulsant actions in rats and mice. J Pharmacol Exp Ther 1984;228:109-15.
32. Braestrup C, Nielsen EB, Sonnewald U, et al. (R)-N-[4,4-Bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain γ-aminobutyric acid uptake carrier. J Neurochem 1990;54:639-47.
33. Suzdak PD, Frederiksen K, Andersen KE, Sørensen PO, Knutsen LJS, Nielsen EB. NNC-711, a novel potent and selective γ-aminobutyric acid uptake inhibitor: pharmacological characterization. Eur J Pharmacol 1992;223:189-98.
34. Larsson OM, Falch E, Krogsgaard-Larsen P, Schousboe A. Kinetic characterization of inhibition of γ-aminobutyric acid uptake into cultured neurons and astrocytes by 4,4-diphenyl-3-butenyl derivatives of nipecotic acid and guvacine. J Neurochem 1988;50: 818-23.
35. Taylor CP, Vartanian MG, Schwarz RD, Rock DM, Callahan MJ, Davis MD. Pharmacology of CI-966: a potent GABA uptake inhibitor. In vitro and in experimental animals. Drugs Dev Res 1990; 21:195-215.
36. Sedman AJ, Gilmet GP, Sayed AJ, Posvar EL. Initial human safety and tolerance study of a GABA uptake inhibitor, CI-966: potential role of GABA as a mediator in the pathogenesis of schizophrenia and mania. Drugs Dev Res 1990;21:235-42.
37. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJS, Sonnewald U, Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991;196:257-66.
38. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995;36:605-11.
39. Smith SE, Parvez NS, Chapman AG, Meldrum BS. The gamma-aminobutyric acid uptake inhibitor, tiagabine, is anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol 1995;273: 259-65.
40. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine; a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995;36:616-26.
41. Dalby NO, Nielsen EB. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res 1997;28:63-72.
42. Morimoto K, Sato H, Yamamoto Y, Watanabe T, Suwaki H. Antiepileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy. Epilepsia 1997;38:966-74.
43. Coenen AML, Blezer EHM, Van Luijtelaar ELJM. Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram, spike-wave discharges and behaviour of rats. Epilepsy Res 1995;21: 89-94.
44. Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997;38:408-14.
45. Walton NY, Gunawan S, Treiman DM. Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine. Epilepsy Res 1994;19:237-44.
46. Halonen T, Nissinen J, Jansen JA, Pitkanen A. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Eur J Pharmacol 1996;299:69-81.
47. Dalby NO, Nielsen EB. Tiagabine exerts an anti-epileptogenic effect amygdala kindling epileptogenesis in the rat. Neurosci Lett 1997;229:135-7.
48. Fink-Jensen A, Suzdak PD, Swedberg MDB, Judge ME, Hansen L, Nielsen PG. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992;220:197-201.
49. During M, Mattson R, Scheyer R, et al. The effect of tiagabine HCl on extracellular GABA levels in the human hippocampus. [Abstract]. Epilepsia 1992;33(suppl 3):83.
50. Thompson SM, Gähwiler BH. Effects of the GABA uptake inhibitor tiagabine on inhibitory synaptic potentials in rat hippocampal slice cultures. J Neurophysiol 1992;67:1698-701.
51. Roepstorff A, Lambert JDC. Comparison of the effect of the GABA uptake blockers, tiagabine and nipecotic acid, on inhibitory synaptic efficacy in hippocampal CA1 neurones. Neurosci Lett 1992;146:131-4.
52. Borden LA, Dhar TGM, Smith KE, Weinshank RL, Branchek TA, Gluchowski C. Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol Mol Pharmacol 1994;269:219-24.
53. Thomsen C, Sorensen PO, Egebjerg J. 1-(3-(9H-carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter. Br J Pharmacol 1997;120:983-5.
54. Dalby NO, Thomsen C, Fink-Jensen A, et al. Anticonvulsant properties of two GABA uptake inhibitors NNC 05-2045 and NNC 05-2090, not acting preferentially on GAT-1. Epilepsy Res 1997; 28:51-61.
55. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995;21:37-42.
56. Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures - a randomized, add-on, dose-response trial. Arch Neurol 1998;55:56-62.
57. Adkins JC, Noble S. Tiagabine - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998;55:437-60.
58. Kälviäinen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K. A double-blind, placebo controlled trial of tiagabine given three times daily as add-on therapy for refractory partial seizures. Epilepsy Res 1998;30:31-40.
59. Lancel M, Faulhaber J, Deisz RA. Effect of the GABA uptake inhibitor tiagabine on sleep and EEG power spectra in the rat. Br J Pharmacol 1998;123:1471-7.
60. Sheardown MJ, Weis JU, Knutsen LJ, Swedberg M, Suzdak PD. Analgesic effect of the GABA uptake inhibitor NO-328 (N-(4,4-Dl(3-methyl-2-thienyl) but-3-en-1-yl) nipecotic acid) [Abstract]. Soc Neurosci Abstr 1989;15, PI:602.
61. Nielsen EB. Anxiolytic effect of NO-328, a GABA-uptake inhibitor [Abstract]. Psychopharmacology 1988;96:S42.
62. Johansen FF, Diemer NH. Enhancement of GABA neurotransmission after cerebral ischaemia in the rat reduces loss of hippocampal CA1 pyramidal cells. Acta Neurol Scand 1991;84:1-6.
63. Inglefield JR, Perry JM, Schwartz RD. Post-ischemic inhibition of GABA reuptake by tiagabine slows neuronal death in the gerbil hippocampus. Hippocampus 1995;5:460-8.